about
TICdb: a collection of gene-mapped translocation breakpoints in cancerNIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5;14)(q33;q24) and an imatinib-responsive myeloproliferative disorderSignatures of selection in fusion transcripts resulting from chromosomal translocations in human cancerTransforming and tumorigenic activity of JAK2 by fusion to BCR: molecular mechanisms of action of a novel BCR-JAK2 tyrosine-kinase.Genomic hallmarks of genes involved in chromosomal translocations in hematological cancer.Oncofuse: a computational framework for the prediction of the oncogenic potential of gene fusions.Effects of Sample Size and Full Sibs on Genetic Diversity Characterization: A Case Study of Three Syntopic Iberian Pond-Breeding Amphibians.CBL mutations in myeloproliferative neoplasms are also found in the gene's proline-rich domain and in patients with the V617FJAK2.p.Y317H is a new JAK2 gain-of-function mutation affecting the FERM domain in a myelofibrosis patient with CALR mutation.Degree and distribution of variability in the 5' untranslated, E1, E2/NS1 and NS5 regions of the hepatitis C virus (HCV).The GCGGAA gene-regulatory motif of herpes simplex virus type-1 is also found in hepatitis C virus.A new potential oncogenic mutation in the FERM domain of JAK2 in BCR/ABL1-negative and V617F-negative chronic myeloproliferative neoplasms revealed by a comprehensive screening of 17 tyrosine kinase coding genes.CBL RING finger deletions are common in core-binding factor acute myeloid leukemias.Novel translocations that disrupt the platelet-derived growth factor receptor beta (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disorders.Molecular heterogeneity in AML/MDS patients with 3q21q26 rearrangements.Cryptic ins(2;11) with clonal evolution showing amplification of 11q23-q25 either on hsr(11) or on dmin, in a patient with AML-M2.Clinical variability of patients with the t(6;8)(q27;p12) and FGFR1OP-FGFR1 fusion: two further cases.Reliable effective number of breeders/adult census size ratios in seasonal-breeding species: Opportunity for integrative demographic inferences based on capture-mark-recapture data and multilocus genotypes.Dihomo-gamma-linolenic acid induces fat loss in C. elegans in an omega-3-independent manner by promoting peroxisomal fatty acid β-oxidation.Bioinformatic analyses of CALR mutations in myeloproliferative neoplasms support a role in signaling.Constitutional genetic association with CALR mutations?LNK can also be mutated outside PH and SH2 domains in myeloproliferative neoplasms with and without V617FJAK2 mutation.Multiplex PCR assay for the identification and differentiation of all Brucella species and the vaccine strains Brucella abortus S19 and RB51 and Brucella melitensis Rev1.A new KRT16 mutation associated with a phenotype of pachyonychia congenita.JAK2 V617F mutation in classic chronic myeloproliferative diseases: a report on a series of 349 patientsMethylation status of SOCS1 and SOCS3 in BCR-ABL negative and JAK2V617F negative chronic myeloproliferative neoplasmsA simple approach for classifying new mutations as somatic or germinal in DNA samples lacking paired tissueA meta-analysis ofTET2mutations shows a distinct distribution pattern inde novoacute myeloid leukemia and chronic myelomonocytic leukemiaLow frequency of JAK2 exon 12 mutations in classic and atypical CMPDsMethylation of CpG dinucleotides and/or CCWGG motifs at the promoter of TP53 correlates with decreased gene expression in a subset of acute lymphoblastic leukemia patientsTP53is frequently altered by methylation, mutation, and/or deletion in acute lymphoblastic leukaemiaAnalysis of genes encoding epigenetic regulators in myeloproliferative neoplasms: Coexistence of a novel mutation in a patient with a p.V617F positive myelofibrosisPhenolic Compounds Inhibit 3T3-L1 Adipogenesis Depending on the Stage of Differentiation and Their Binding Affinity to PPARγCytogenetic profile of myelodysplastic syndromes with complex karyotypes: an analysis using spectral karyotypingCyclodextrin-grafted poly(anhydride) nanoparticles for oral glibenclamide administration. In vivo evaluation using C. elegansBorago officinalis seed oil (BSO), a natural source of omega-6 fatty acids, attenuates fat accumulation by activating peroxisomal beta-oxidation both in C. elegans and in diet-induced obese ratsLow doses of cocoa extract supplementation ameliorate diet-induced obesity and insulin resistance in ratsA Simple and a Reliable Method to Quantify Antioxidant Activity In VivoA combination of borage seed oil and quercetin reduces fat accumulation and improves insulin sensitivity in obese rats
P50
Q27496616-8072D705-1374-48AF-A55C-817F3CD919C2Q28256823-1F6064FD-070F-4B66-BB42-4A82F1E4E95CQ33417270-79A4F0C2-CF29-4CF2-A9AA-8F060ABD3FE0Q34182738-D7EE722E-9ED6-4AA0-9EFB-8DE58D669F12Q34510118-769BA7BF-EC10-4412-835B-EA2BE6E8D26BQ34954993-A5AC02C3-EA8C-4D63-999B-756A44C65D25Q38690752-067EB5FE-0F0C-42F5-93A5-2E0F3C5664DCQ39399799-F4E981A2-0605-4C74-B255-E32EE5BC7009Q42341711-10D9C5DA-643A-4288-ABE6-AE24E42243E4Q42990146-52370F2B-4A51-42F2-96D9-2912F9731DC1Q43040794-3ECB8DD9-B458-4C06-A11F-44B501241303Q43086317-6AB87D81-20D2-4FA4-A150-96F84A5536C3Q44076785-5768046C-E304-4EB4-9B91-63CBE472C121Q44287656-28DE7531-D603-4072-874A-58F16B22639BQ44893063-CC45C7D8-4002-4E20-AD76-4278B7242F4BQ45106457-A988C732-4E52-49CD-BD4E-9FB52EB4A444Q45166943-E23D611C-D80B-484F-952D-ACF741956E21Q46241620-3DDA8B51-9BC1-4899-9571-10AF44539D31Q49710945-26765278-B863-41F9-9D67-D600FECFB165Q51080076-B150B291-BC47-4C46-9616-E22B12A5F430Q52836539-922594E5-8E29-42E3-B62D-358CDD15AC13Q54571457-7B88A8DC-1C1F-4153-8446-7ED087BC666BQ54610404-55ED08A6-A2BF-438C-8129-BDDD8DF05FDCQ54775852-FF915D7F-F19E-4CBC-8996-7EDF15398333Q58455740-0F6F4B2B-9342-47C3-B530-33C0AC8D203EQ60668456-814B1772-9FEC-4D6B-B3AD-B17A40283F53Q61882499-AB222333-D6BD-4E52-9263-9559FACBDCA8Q61882501-CE336C68-90F1-4BBC-88DE-C2EB3D810ECEQ61882504-93927015-8E37-4CDC-A1BB-713E123D85C4Q61882506-0F87C0B2-35C0-4D5D-84AB-ACDF6A7F23D7Q61882507-4B7BC0AE-7CC4-438E-80CB-B21A8977C001Q64067556-513E5CB9-B95C-4B42-85DC-DB5D90E6B18AQ64084641-275D9CFB-6CA8-4D58-B71B-D515B0CDCC4DQ80483305-FDD09AE6-7806-4A58-9FCD-9B984CEAB4EDQ88905976-04D0D907-6BEE-4D93-9FF6-5954980815E4Q90456079-D6773F37-02E5-42DD-9F3B-72A405B7F559Q91982499-313DF1E5-B5A1-4516-8BF6-E4A05C4D619AQ92246516-D57247FB-52D6-4E23-868D-449EF9658732Q94548465-89B86F46-35FF-42C4-AC56-5B3BADE0C7DA
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
José Luis Vizmanos
@ast
José Luis Vizmanos
@en
José Luis Vizmanos
@es
José Luis Vizmanos
@nl
José Luis Vizmanos
@sl
type
label
José Luis Vizmanos
@ast
José Luis Vizmanos
@en
José Luis Vizmanos
@es
José Luis Vizmanos
@nl
José Luis Vizmanos
@sl
prefLabel
José Luis Vizmanos
@ast
José Luis Vizmanos
@en
José Luis Vizmanos
@es
José Luis Vizmanos
@nl
José Luis Vizmanos
@sl
P1053
G-2833-2012
P106
P21
P31
P3829
P496
0000-0001-7416-3679